Feiyan Mo

Postdoc at Penn Medicine | NCI K00 Fellow | T cell therapies for cancer and alloimmune complications

[Feiyan Mo @feiyan_mo]

@CGFigE @NIH @theNCI @MJMitchell_Lab Congrats!!

[Feiyan Mo @feiyan_mo]

@CAGTHouston @MaxMamonkin @ASGCTherapy Congratulations Max @MaxMamonkin !

[Feiyan Mo @feiyan_mo]

@MaxMamonkin @CPRITTexas @bcmhouston @CAGTHouston This is fantastic! Congrats!

[From the Labs at Baylor College of Medicine @BCMFromtheLabs]

#GraftvsHost disease & #leukemia relapse account for most patient deaths after #HSCT treatment. Here, Drs. @MaxMamonkin, @feiyan_mo et al designed a way to reduce such complications. @BloodJournal @BCMCancerCenter #bloodCancer @BCMGradSchool https://t.co/NLjbG8BjI2 @bcmhouston

[Feiyan Mo @feiyan_mo]

@Bailee_Kain @bcmhouston Congratulations!!

[Max Mamonkin @MaxMamonkin]

CAR T have many applications beyond direct tumor targeting. Here, we engineer T-cells to prevent acute GvHD after alloHSCT. We show targeted ablation of OX40+ T-cells reversed fatal xeno-GvHD and could be combined with a CAR to prevent leukemia relapse 1/
https://t.co/5sR4BBjiJu

[From the Labs at Baylor College of Medicine @BCMFromtheLabs]

Drs. @MaxMamonkin, @feiyan_mo et al developed a promising approach to mitigate complications of #leukemia treatment. #GvHD #CARTcells @CAGTHouston @BCMCancerCenter @BloodJournal @BCMGradSchool @BostonChildrens #cancer https://t.co/HAocPMHXHV

[Max Mamonkin @MaxMamonkin]

Back in 2018, we were working to move our CD7 CARTs (CRISPR-edited for CD7 to avoid fratricide) to a Phase I but the regulatory hurdles for gene-edited CARTs were too high for a small academic group. That got us thinking, do we need gene editing at all? 1/
https://t.co/ugKRwmvf6b

[Feiyan Mo @feiyan_mo]

@Xiaoyun_D Thanks Dr. Ding 😉 Do come and visit me soon!!

[Feiyan Mo @feiyan_mo]

Excited to share that I finally passed defense! I feel truly honored to have such wonderful mentors and am grateful to everyone who supported me along this journey. I will start working as a postdoc in the Stanger lab at UPenn next month - looking forward to the next adventure!

[Max Mamonkin @MaxMamonkin]

Superstar!

[Feiyan Mo @feiyan_mo]

@JTZoine @MaxMamonkin @ASGCTherapy Thank you! And congrats to you, too - I really enjoyed your talks!

[Feiyan Mo @feiyan_mo]

Thanks @ASGCTherapy for selection - really honored to receive this award! And always grateful to my wonderful mentors, lab mates and collaborators.

[Max Mamonkin @MaxMamonkin]

Huge congratulations to @feiyan_mo for receiving the Excellence in Research Award from @ASGCTherapy for a top-scoring abstract on targeting OX40+ T-cells for the therapy of aGvHD. She will present her work tomorrow #ASGCT2022 #proudPImoment

[EBMT @TheEBMT]

👩‍🔬🔬In this exciting new study including in #EBMT22 Presidential Symposium, @feiyan_mo explains how her team looked to harness the potency of engineered T-cells and redirect them against pathogenic T-cells that mediate #GvHD. More here ⬇️
https://t.co/CYc4Z9IrWo
@MaxMamonkin

[Feiyan Mo @feiyan_mo]

@Bailee_Kain Happy belated birthday!

[Feiyan Mo @feiyan_mo]

Really honored that our work made it to the Presidential Symposium at #EBMT2022 Special thanks to my wonderful mentors and collaborators. @MaxMamonkin @CAGTHouston

[ALL Hub @ALL_Hub_]

Congress| #EBMT2022| @feiyan_mo, @bcmhouston discusses targeted ablation of activated donor CD4+ T-cells with engineered T-cells attenuating acute GvHD while preserving protective CD8+ T-cell immunity and showed feasibility for a bi-functional CAR-ADR T-cell product #ALLsm #leusm

[ALL Hub @ALL_Hub_]

Congress| #EBMT2022| @feiyan_mo, @bcmhouston discusses targeted ablation of activated donor CD4+ T-cells with engineered T-cells attenuating acute GvHD while preserving protective CD8+ T-cell immunity and showed feasibility for a bi-functional CAR-ADR T-cell product #ALLsm #leusm

[Max Mamonkin @MaxMamonkin]

Very excited our story on rejection-resistant OTS CAR T-cells made the cover of Nat Biotechnol! @feiyan_mo @diogo_g_silva @sampyehn @LLSusa

[Max Mamonkin @MaxMamonkin]

Excited to present at the #BMTWorkshop our ongoing work with @feiyan_mo on engineering T-cells for the therapy of aGvHD. Great format, excellent speakers and helpful feedback from top GvHD experts. Loved it! https://t.co/svpV9ahNpR

[Max Mamonkin @MaxMamonkin]

Excellent podcast by Michele Sadelain and Irene Jarchum discussing off-the-shelf CAR T-cells. Pros and cons of various strategies to prevent host-versus-graft and graft-versus-host activities, including our recent work on 4-1BB specific anti-rejection receptor. Very humbling!

[Feiyan Mo @feiyan_mo]

@Xiaoyun_D @BCMFromtheLabs Congrats!!!